ArticleNPJ precision oncology2026

Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors.

Gerhard Jungwirth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.